By using the MS-based proteomic analysis, Padden et al. reported that ANXA1 and ANXA10 are promising biomarkers distinguishing ICC from pancreatic cancer by immunohistochemistry [39]. This evidence concerns the gene ANXA10 and familial pancreatic carcinoma.